TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop

29 Sep 2011

by Working Group

Posted in Events, TB Drug Development, TB News
Tags: animal models, China, clinical trials, conferences and meetings, drug discovery, india, innovations, Lilly, online tools, pharma, publications, r&d

TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop

On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development.

The presentations from the 4th International Workshop on Clin. Pharm. of TB Drugs are available [click here].

Key abstracts from ICAAC were:

Authors	Abstract Title
Diacon, R. Dawson, C. Van Niekerk, N. Erondu, A. Ginsberg	Pyrazinamide Increases the Early Bactericidal Activity of TMC207 and PA-824 in Patients with Newly Diagnosed, Smear-positive Pulmonary Tuberculosis
A. Diacon, R. Dawson, C. Van Niekerk, N. Erondu, A. Ginsberg	Phase 2 Trial of a Novel 3-Drug Regimen for Both MDR and Drug Sensitive (DS) TB
R. Tasneen, S. Li, K. Andries, K. Mdluli, E. Nuermberger	Novel TMC207-containing Regimens Have Sterilizing Activity In Murine Tuberculosis
H. Huang , K. Liu, D. Zhang, B. Liu, G. Zhang, H. Zhang, Y. Li, Master C. Zhang, Y. Liu, J. Wang, Y. Lu, M. Zheng, B. Wang, T. Yang, X. Li, C. Li, C. B. Cooper, Z. Ma, D. Yin	SAR of Riminophenazine Class and Discovery of New Anti-tuberculosis Agents Active Against Multidrug-Resistant Tuberculosis
Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu, H. Jin, D. Yin, H. Huang, Z. Ma	Clofazimine Analogs with Superior Efficacy against Experimental Tuberculosis and Reduced Potential for Tissue Discoloration
M. Upton, A. Shadiack, Z. Ma, Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu, H. Jin, D. Yin, H. Huang	Anti-tubercular Clofazimine Analogs that Demonstrate a Range of Tissue Distribution Patterns Following Eight Weeks Dosing to Mice
K. C. Chang, W. W. Yew, S. W. Cheung, C. C. Leung	Extensively Drug-resistant Tuberculosis (XDR-TB) Treated with Daily/ Intermittent Linezolid
L. Manzini, M. Parracino, D. Iemmi, G. Lapadula, A. Gori, E. Girardi, C. Mussini	Tolerability of Moxifloxacin as Part of Anti-Tuberculous Treatment